Frequencies of an Immunogenic HER-2/Ineu/I Epitope of CD8+ T Lymphocytes Predict Favorable Clinical...
Frequencies of an Immunogenic HER-2/Ineu/I Epitope of CD8+ T Lymphocytes Predict Favorable Clinical Outcomes in Prostate Cancer
About this item
Full title
Author / Creator
Publisher
MDPI AG
Journal title
Language
English
Formats
Publication information
Publisher
MDPI AG
Subjects
More information
Scope and Contents
Contents
HER-2/neu is the human epidermal growth factor receptor 2, which is associated with the progression of prostate cancer (PCa). HER-2/neu-specific T cell immunity has been shown to predict immunologic and clinical responses in PCa patients treated with HER-2/neu peptide vaccines. However, its prognostic role in PCa patients receiving conventional tre...
Alternative Titles
Full title
Frequencies of an Immunogenic HER-2/Ineu/I Epitope of CD8+ T Lymphocytes Predict Favorable Clinical Outcomes in Prostate Cancer
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_gale_infotracmisc_A751927031
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_gale_infotracmisc_A751927031
Other Identifiers
ISSN
1422-0067
DOI
10.3390/ijms24065954
